Nuts and Bolts : Microfluidics for the Production of Biomaterials by Fontana, Flavia et al.
Advanced Materials Technologies
 




Full Title: Nuts and Bolts: Microfluidics for the Production of Biomaterials
Article Type: Invited Review
Section/Category: By Invitation Only: Microfluidics
Keywords: Microfluidics;  biomaterials;  Biosensors;  Drug Delivery Systems










Dear Dr. Jovia Jing,
I am submitting the revised manuscript (Invited Review, No. admt.201800611) entitled
“Nuts and Bolts: Microfluidics for the Production of Biomaterials”” for consideration and
publication as a Review paper in Advanced Materials Technologies.
We would like first to thank you and the reviewer for the positive and constructive
comments for the improvement of our article. All the comments raised in the reviewer’
reports have been fully addressed. Please find enclosed the reply to the reviewer’
reports, which also describes the changes made in the manuscript.
We believe that the changes introduced to the manuscript have further improved it and





Dr. Hélder A. Santos, D.Sc. (Chem. Eng.), Associate Professor, Head of Division
Head of the Division of Pharmaceutical Chemistry and Technology
Head of the Nanomedicines and Biomedical Engineering Group
Head of Preclinical Drug Formulation and Analysis Group
Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland;
&




Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Do you or any of your co-authors have a
conflict of interest to declare?
No. The authors declare no conflict of interest.
Corresponding Author Secondary
Information:
Corresponding Author's Institution: University of Helsinki
Corresponding Author's Secondary
Institution:
First Author: Flavia Fontana
First Author Secondary Information:
Order of Authors: Flavia Fontana
João Pedro Martins
Giulia Torrieri
Helder Santos, D.Sc. (Chem. Eng.)
Order of Authors Secondary Information:
Abstract: Nanotechnology holds the promise of bringing revolutionary therapeutic strategies into
the clinic. However, an enormous fraction of the currently proposed nanotechnology-
based therapies suffers from lack of reproducibility, complexity, high costs, and scale-
up related issues. For these reasons, the research community has been moving
towards the miniaturization of biomaterials and fabrication methods. Customizable
microfluidic-based products have gained tremendous relevance in the development of
biomedical technologies. This review provides an overview of different materials that
can be used for the fabrication of microfluidic devices, as well as the other parameters
influencing the production of biomaterials and biosensors. Moreover, several advanced
microfluidic-based technologies that have been designed to overcome the current
challenges of cancer, immunotherapy, and diabetes therapy, among others are
described. Then, the pros and cons of microfluidics as alternative to conventional
preparation methods, and the challenges of translating this technique to an industrial
context are highlighted. Overall, microfluidic technologies and their accessibility to the
research community offer a set of exciting opportunities to bridge the development of
innovative therapies and their commercialization in the foreseeable future.




DOI: 10.1002/ ((please add manuscript number))  
Article type: Review 
 
 
Nuts and Bolts: Microfluidics for the Production of Biomaterials 
 
Flavia Fontana†, João P. Martins†, Giulia Torrieri, and Hélder A. Santos*  
 
F. Fontana, J. P. Martins, G. Torrieri, Prof. H. A. Santos 
Drug Research Program and Division of Pharmaceutical Chemistry and Technology 
Faculty of Pharmacy 
University of Helsinki 
FI-00014, Helsinki, Finland 
E-mail: helder.santos@helsinki.fi 
 
Prof. Hélder A. Santos 
Helsinki Institute of Life Sciences (HiLIFE) 
University of Helsinki, 
FI-00014, Helsinki, Finland  
 
Keywords: Microfluidics, Biomaterials, Biosensors, Drug Delivery Systems 
 








































































Nanotechnology holds the promise of bringing revolutionary therapeutic strategies into the 
clinic. However, an enormous fraction of the currently proposed nanotechnology-based 
therapies suffers from lack of reproducibility, complexity, high costs, and scale-up related 
issues. For these reasons, the research community has been moving towards the 
miniaturization of biomaterials and fabrication methods. Customizable microfluidic-based 
products have gained tremendous relevance in the development of biomedical technologies. 
This review provides an overview of different materials that can be used for the fabrication of 
microfluidic devices, as well as the other parameters influencing the production of 
biomaterials and biosensors. Moreover, several advanced microfluidic-based technologies that 
have been designed to overcome the current challenges of cancer, immunotherapy, and 
diabetes therapy, among others are described. Then, the pros and cons of microfluidics as 
alternative to conventional preparation methods, and the challenges of translating this 
technique to an industrial context are highlighted. Overall, microfluidic technologies and their 
accessibility to the research community offer a set of exciting opportunities to bridge the 






































































Nanotechnology is an ever-growing field that brings closely together biology and advanced 
technologies, with the potential to provide ground-breaking solutions in the treatment of 
several diseases, such as cancer or diabetes. It allows for the manipulation of materials at the 
nanoscale with an extraordinary degree of precision, and it holds the promise to revolutionize 
the field of medicine through manifold applications, from pharmaceutical products to medical 
devices.[1] Over the years, nanotechnology has been enabling the delivery of poorly water-
soluble drugs, including some previously considered as undevelopable, and to allow for 
targeted drug delivery, thereby improving drug bioavailability and specificity, while 
minimizing unwanted side effects.[1-2] Additionally, nanosized biomedical devices such as 
prostheses and implants have been showing a tremendous potential in a wide range of 
applications.[3] Such potential has been translated into an enormous amount of publications, 
patents, and start-up companies with one common goal, bring nanotechnology into the clinic. 
However, all the enthusiasm surrounding the new biomedical technologies is often deflated 
before any clinical/commercial achievement.[4] Despite the fairly predictable improvement of 
nanotechnology-based therapies over conventional treatments, some constraints related to the 
technologies themselves have now started to be heard, including complexity and costs of the 
manufacturing processes, which create a significant hurdle for drug companies.[1, 4] For these 
reasons, the scientific progress that is translated into clinical applications is reduced.[5] 
Indeed, conventional methods of preparation of nanotechnology-based therapies suffer from 
complex experimental set-ups, poor controllability and reproducibility, and are further 
associated with scale-up feasibility issues.[6] The long development and evaluation processes, 
together with their associated high costs are undeniably hindering the launching of novel 
nanotechnology-based systems into the market.[6] It is therefore crucial to find alternative 
fabrication techniques that can help nanotechnology to have the greatest clinical impact in the 





































































A tremendous technological progress has taken place in the biomedical field over the past 
decades, particularly towards the miniaturization of biomaterials and their respective 
fabrication methods, in order to replace conventional macrosized benchtop equipment.[7] 
Microfluidics has emerged in the early 1950s,[8] but its application was only largely widened 
after George M. Whitesides research group reported, in 1998, the preparation of microscopic 
channels based on rapid prototyping of poly(dimethylsiloxane) (PDMS) masters using high-
resolution printing and contact lithography.[9]  
The miniaturization of fluidic operations and their high applicability is indeed particularly 
compelling, and therefore, represents a new shift in the fabrication of advanced technologies 
that can replace conventional therapies. The current developments of microfluidic-assisted 
fabrication technologies are based in a variety of theoretical considerations and advanced 
knowledge, involving the geometries of the microfluidic devices, the materials used for their 
preparation, basic fluidic principles, flow patterns and regimes inside the microfluidic 
channels, and have been described in a great number of related publications in this area.[6, 10] 
In this review, we first discuss the materials used for the fabrication of microfluidic devices, 
and other parameters influencing the production of biomaterials. Additionally, we 
acknowledge the most recent applications of microfluidics in cancer, immunology, and 
diabetes research areas, among others. Finally, we address the pros and cons of microfluidics, 
and the challenges of translating this technique to an industrial context. 
 
2. Material Development 
During the last decades, multiple microfluidics platforms different for the fabrication material, 
for the geometrical configuration and for the operative conditions have been reported in 
literature. In this section we will review the nuts and bolts of this technique applied to the 





































































Microfluidics chips have been fabricated over a variety of substrates, including glass, 
polydimethylsiloxane (PDMS), polycarbonate, poly (methyl methacrylate) (PMMA), cyclic 
olefin copolymer, polyetheretherketone, polyimide plastic resin, stainless steel, single-crystal 
silicon.[11] Each of these materials presents advantages and disadvantages, based on the final 
application of the platform. As an example, polymeric flexible substrate (PDMS, PMMA, 
etc.) have been extensively employed in point-of-care diagnostics thanks to their favorable 
properties (mainly flexibility, optical transparency, heat conductivity, electrochemical 
resistance).[12] However, PDMS chips are less suitable for application in the synthesis of drug 
delivery systems due to their reactivity towards organic solvents, the low withstandingness to 
high pressures, the absorption of small inorganic molecules, and the problematic, and only 
temporary, hydrophilization of the channels.[13] Glass platforms, on the other hand, resist to 
chemical solvents, do not swell, and present low electrical conductivity, smooth surface, 
surface easily modifiable.[13a, 14]  
The fabrication methods differ between the different platforms: in general, they rely on e.g. 
lithographic methods, etching, molding.[13a] A summary of these methods is presented in 
Table 1. 
Table 1. Fabrication methods of microfluidics platforms based on the fabrication material. 
Modified and reprinted with permission.[13a] © 2013, Elsevier B.V.  
 
Platform Material Fabrication Methods Final Surface Ref. 
Single-crystal Silicon 
Photolithograpy, Anisotropic Wet 
Etching, Deep Reactive Ion Etching 






Soft Lithography, Combination of 
Micromilling, Molding and Soft 
lithography to Create Circular 
Channels 
Hydrophobic, can be Hydrophilic by Plasma Oxidation, 
Sol-Gel Coating with Silica or Titania, Layer-by-layer 
Deposition of Polyelectrolytes, UV Polymerization of 
Acrylic acid, UV Irradiation, Chemical Vapour 
Deposition, Antifouling Coatings 
[11b, 
16] 
Glass (different types) 
Mechanical cutting, Chemical Dry 




Hot Embossing, Injection Molding, 
Nanoimprint Lithography, Laser 
Ablation 
Hydrophobic [18] 
Polyurethane Soft Lithography Hydrophobic [19] 
Poly (methyl 
methacrylate) (PMMA) 
Hot Embossing Lithography, 
Injection Molding, Mechanical 








































































Stainless Steel Mechanical Cutting Hydrophilic [21] 
Glass Capillaries 
Micropipette Pulling, Microforge, 
Manual Sanding of the Orifice, 
Gluing to the Glass Slide 




Platform for Glass 
Capillaries 
Micropipette Pulling, Microforge, 
Manual Sanding of the Orifice 
Hydrophilic, with Modifications Hydrophobic [23] 
Paper (Paper based-
microfluidics) 
Cutting, Wax printing, Inkjet printing, 
Photolithography, DLP Printing 
Hydrophilic, with Modifications Hydrophobic [24] 
 
Moving forward, the next element characterizing a microfluidics platform is its geometry, as 
presented in Figure 1. Microfluidics platforms are usually based on the exploitation of the 
geometries to achieve a laminal flow within the channels. A laminar flow corresponds to flow 
regimens presenting low Reynolds number (Re), dimensionless parameter describing the 
interaction between inertial to viscous forces in the channel.[25] In these conditions, the 
viscous forces are predominant over the inertial ones, allowing a high degree of control over 
the fluidic, and thereby, on the nanosystems engineered by microfluidics.[6, 10a, 26] Depending 
on the final drug delivery system, a suitable geometry can be engineered. As an example, 
microparticles are produced by droplet, emulsion-based microfluidics, with different platform 
configurations depending on the need for single or multiple emulsions, which correlates with 
the need for a core shell structure in the microparticle (Figure 1a).[11a, 27] Microfluidics devices 
have also been used in the layer-by-layer production of microcapsules (Figure 1d). For 
example, core particles were coated either by liquid crystals and/or by polymers, with 
intermediate washing steps.[28] Alternatively, microfluidics can serve in the soft lithography of 






































































Figure 1. General types of geometries employed in the production of micro- and 
nanoparticles. a) Production of microparticles by droplets emulsion; b) and c) preparation of 
nanoparticles by flow focusing and microvortices nanoprecipitation, respectively; d) 
engineering of multistage particles by subsequent coating with different polymers in 
subsequent T-junctions; e) production of particles by flow lithography. Reprinted with 
permission.[30] © 2014, Elsevier B.V. 
 
The term “nanoprecipitation” identifies the formation of nanoparticles caused by a change in 
the type of solvent, from good solvent to non-solvent.[31] Research in the process highlighted 
the presence of three different stages, namely nucleation, nucleus growth, and nanoparticle 
formation, which are highly dependent on the mixing time between solvent and non-
solvent.[32] The laminar and jetting flow regimens in microfluidics devices enable a very rapid 
micromixing, which in turn enables a high degree of control on the size and size distribution 
of the particles produced.[6] Nanoprecipitation is usually achieved in platforms displaying 
flow focusing geometry.[32-33] In PDMS microfluidics platforms, the continuous phase coming 
from the lateral channels squeezes the dispersed phase into a thin stream, resulting into 
enhanced mixing in lower time, as depicted in Figure 2a.[34] The dispersed phase contains the 





































































polymer, while still being miscible with the dispersed solvent.[10a] This platform can produce 
polymeric NPs with homogenous size distribution.[32] However, in this configuration, the flow 
is focused only in 2D, which may cause precipitation of the particles along the walls of the 
channel, blocking it.[35] Thereby, a further development involved the engineering of a 3D flow 
focusing device (Figure 2b).[35] In this device, the dispersed phase containing the polymer is 
first focused vertically by two layers of the same solvent, before being horizontally focused 
by the antisolvent.[35] 
 
Figure 2. Hydrodynamic flow focusing (HFF) devices in PDMS. a) 2D-HFF: the flow is 
focused only horizontally by the antisolvent. Reprinted with permission.[32] © 2008, American 
Chemical Society; b) 3D-HFF, the flow is first focused vertically by two layers of solvent, 
before the horizontal focusing achieved by the continuous phase. Reprinted with 






































































An alternative approach can achieve the 3D hydrodynamic flow focusing into glass capillaries 
platforms. For example, concentric capillaries are assembled and fused into a bigger 
polymeric tube (Figure 3a);[36] in an alternative, easier configuration, where a glass capillary 
is first pulled and sanded to present an orifice of predetermined dimensions, before being 
coaxially aligned within a bigger capillary (Figure 3b).[23, 37]  
 
Figure 3. Glass capillary 3DHFF configurations. a) Platform constituted by 7 capillaries 
assembled and fused together into a polymeric tube for the production of liposomes. 
Reprinted with permission from.[36] © 2014, The Royal Society of Chemistry; b) 
Microfluidics chip constituted by glass capillaries into a flow focusing configuration: a 
smaller, pointed, capillary is coaxially aligned within a bigger capillary. Reprinted with 
permission.[23] © 2016, Elsevier B.V. 
 
In particular, the second type of glass capillary platform presented is highly versatile, 
allowing the possibility to achieve nanoprecipitation in conditions of microvortexes, at lower 





































































yield up to 250 g day-1.[37] Further engineering of this platform produced a microfluidics chip 
composed by two sequential precipitation areas, to produced core-shell particles with 
extremely high yield (up to 700 g day-1).[38] 
In the production of NPs by nanoprecipitation in microfluidics, the viscosity of the dispersed 
phase plays a role in the final size of the systems. As a rule of thumb, an increase in the 
viscosity determines an increase in the size of the NPs, due to the prolonging of the mixing 
time determined by a decrease in the diffusiveness of the more viscous solvent (Figure 4a).[37, 
39] A similar effect is observed also when the viscosity of the continuous phase is increased by 
addition of surfactants and other stabilizers: more viscous solutions (e.g., poly vinyl alcohol) 
lead to an increase in the particle size; when positively charged phospholipids are employed, 
they tend to adsorb on the surface of the particle, changing its surface charge to positive 






































































Figure 4. Parameters affecting the size of NPs produced by nanoprecipitation. a) Effect of the 
viscosity of the dispersed phase: solvents with different viscosities were tested in the 
preparation of acetalated dextan NPs. b) Effect of the viscosity of the continuous phase: the 
addition of surfactants with higher viscosity produces an increase in the particle size; c) effect 





































































adsorbed on the particles, as shown by the change in the particle’s surface charge. Reprinted 
with permission.[37] © 2015. Wiley – VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
In summary, the size and yield of NPs, amongst other parameters, are influenced by the type 
of platform chosen (type of material and geometry), together with parameters belonging both 
to the dispersed phase (e.g., viscosity of the organic solvent) and the continuous phase 
(viscosity of the continuous phase, type and charge of surfactants/lipids added to the solution). 




Microfluidics, both as platform for the preparation of biomaterial and as sensor, has been 
employed in a variety of applications in different human diseases, like cancer, immunological 




Cancer still represents one of the leading causes of death worldwide, although the death rate 
has been constantly declining over years with the therapeutic advancements.[41] Nanomedicine 
has been hailed as great promise to enhance the efficacy of the treatments while reducing the 
side effects.[42] Moreover, NPs have the potentiality to actively target tumors cells 
overexpressing certain targets.[43] Another advantage brought by the use of nanosized carriers 
is the possibility to co-deliver different chemotherapeutics, with a precise dosing ratio, and, in 
some cases, in sequential order.[43] However, only 1% of the administered dose accumulates 
in the tumor, opening concerns about the safety and degradability of the 99% ending up off-





































































the disease, the behavior and interaction of a NP in a biological environment, production 
methods and translation from lab scale to industrial production, and the difficult pathway for 
the approval by the regulatory authorities.[45]  
Microfluidics represents a solution to some of the above-mentioned obstacles. More 
specifically, enables the production of NPs with excellent reproducibility and low batch to 
batch variations, while providing also excellent in vitro platforms to study whole libraries of 
NPs (Figure 5a) and the interactions between these particles and the biological 
environment.[43] However, despite the reports of platforms able to produce up to 700 g day-
1,[38] the scale up of some of these microfluidics systems remains problematic.[43] Different 
strategies to enable such scale up in the engineering of emulsion droplets and microparticles 
have been already proposed,[13a] while solutions for NPs are currently being investigated.[38, 46] 
Glass capillary microfluidics platforms were employed to develop stimuli-responsive NPs 
delivering or co-delivering chemotherapeutics, achieving also ultrahigh drug loading (Figure 
5b and c).[47] Specifically, these platforms enabled the successful delivery of 3 different 
chemotherapeutics (sorafenib, methotrexate, paclitaxel) in a nano-in-nano system constituted 
by porous silicon NPs encapsulated within a pH-responsive polymeric layer and modified 
with targeting moieties (Figure 5b).[47a] Moreover, the same platform was adapted for the 
precipitation of pH-responsive nanocomposites for the delivery of sorafenib.[47b] Finally, two 
sequential platforms produced nano-in-nano vectors constituted by a drug nanocrystal core 
coated by a polymeric shell (Figure 5c).[47c] 
Prickly NPs represent a recent player in the field of NPs.[48] They present irregular shape and 
destroy intracellular membranes, controlling cancer cell proliferation. To improve the safety 
of these particles, they were encapsulated into a pH-responsive polymer modified with a 






































































Figure 5. Microfluidics platforms for the synthesis of cancer nanomedicines. a) PDMS 
platform enabling the synthesis of combinatorial libraries of polymeric NPs. Reprinted with 
permission.[50] © American Chemical Society; b) glass capillary system engineering a 





































































(sorafenib, methotrexate, and paclitaxel). Reprinted with permission.[47a] © 2014, Elsevier 
Ltd.; c) sequential platforms for the production of core-shell NPs constituted by sorafenib 
drug nanocrystals in the core coated by a polymeric layer. Reprinted with permission.[47c] © 
2017, Wiley–Verlag GmbH & Co. KGaA, Weinheim. 
 
Rigid nanovescicles for the delivery of hydrophilic cargoes were developed by Zhang et 
al..[51] The authors developed a polymeric microfluidics platform with three separate 
nanoprecipitation areas for the sequential formation of reverse micelles, a polymeric shell 
around the micelles, and, finally, a lipidic layer coating the polymeric shell. This platform 
enabled the simultaneous loading and delivery of doxorubicin and a siRNA, achieving control 
over the tumor growth in an in vivo setting.[51]  
Another interesting platform engineered by microfluidics is formed by hybrid NPs: PLGA 
was modified with biphosphonate to achieve the targeting to the bone tissue, and in particular 
to bone metastases.[52] The particles were further loaded with iron oxide NPs and with 
paclitaxel. 
Sequential nanoprecipitation in microfluidics was adapted for the preparation of chitosan 
NPs,[53] followed by a coating with enteric polymers for drug delivery to colon cancer. The 
external layer allows the particles to pass through the harsh pH of the stomach, before freeing 
the chitosan particles at colonic pH, where the NPs swell and release paclitaxel.[54] 
Finally, microfluidic platforms are currently under investigation as 3D models of the tumor 
and tumor microenvironment.[55] These systems allow the study of the mechanisms 
responsible for the metastases formation and the behavior of cancer cells into blood 
vessels.[56] Alternatively, patient-derived myeloid cells were successfully grown on 
microfluidics platforms, establishing systems for the personalized evaluation of the 





































































In conclusion, microfluidics represents an excellent alternative to bulk methods, both for the 
synthesis of NPs and for the creation of tumor models, addressing and removing some of the 
obstacles preventing a larger diffusion of nanomedicines in cancer therapy.  
 
3.2 Immunotherapy 
Immunotherapy refers to treatments aimed to interfere with patient’s immune systems, with 
the aims of reactivating it (e.g., in case of viral infection and cancer) or to induce 
tolerogenicity (in case of autoimmune diseases).[58] Recently, NPs have gained attention as 
delivery systems for immunomodulatory molecules and as nanovaccines, due to their 
favorable biodistribution and properties that activate the immune system.[58] 
So far, the use of microfluidics for the preparation of nanovaccines has been limited. Glass 
capillary platforms were employed for the synthesis of a core-adjuvant particle, followed by 
membrane extrusion to coat it with membranes derived from cancer cells (Figure 6), 
obtaining a personalized cancer vaccine.[59] This platform was able to activate human immune 






































































Figure 6. High resolution scanning electron microscope images of a) thermally oxidized 
porous silicon nanoparticles (TOPSi); b) TOPSi nanoparticlesencapsulated within a layer of 
acetalated dextran by nanoprecipitation in glass capillary microfluidics (TOPSi@AcDEX); c) 
final system after the coating with cell membrane derived from cancer cells. Reprinted with 
permission.[59] © 2016 WILEY–VCH Verlag GmbH & Co. KGaA, Weinheim.  
 
Another application of microfluidics platforms in immunotherapy is the modelling of the 
interactions between cancer and immune cells in the tumor microenvironment.[60] In particular, 
in one of the first examples, the migration of cells between two compartments, one containing 
tumor cells and the other splenocytes, was assessed in a microfluidic platform, to investigate 
the direction of the migration in wild type and knock out splenocytes (Figure 7a).[61] A 
similar platforms was employed to examine the effect of immunogenic cancer cell death onto 
immune cells activation.[62] Schematics for other platforms have been proposed by 





































































cells flanked by two gel sections containing on one side immune cells and, on the other cancer 
and organ-specific cells. A cytokine gradient would be established throughout the system. The 
purpose of this system would be to evaluate cancer cell metastases to the blood vessels and 
the immune cells migration towards the site of the tumor. A more simple design would 
evaluated the interactions into a 3D tumor microenviroment model without the cytokine 
gradient.[60] 
 
Figure 7. Examples of microchips to study the interaction between cancer and immune cells. 
a) microfluidics platform investigating the migration of splenocytes towards cancer cells. 
Reprinted with permission.[61] © 2014, Springer Nature, published under the Creative 
Commons Attribution-NonCommercial-NoDerivs 4.0 International License; b) ideas to 
evaluate the interaction between the formation of metastases and immune cells under 






































































In summary, microfluidics has excellent potential to provide solutions for application in 
immunology, from the preparation of precisely controlled nanovaccines, to their evaluation 
into complex systems mimicking the tumor microenvironment and the immune organs. 




Diabetes mellitus (DM) is a diagnostic term used for a group of heterogeneous disorders 
caused by abnormal glucose homeostasis.[63] Low insulin secretion by the cells or low insulin 
binding efficiency to its cell membrane receptors leads to high glucose levels, also known as 
hyperglicemia.[64] Chronic hyperglycaemia, in turn, often causes long-term complications 
such as dysfunction or even failure of several organs, including the eyes, kidneys, nerves, 
heart, and blood vessels.[65] The majority of DM cases can be categorized into two 
etiopathogenetic groups, type 1 and type 2.[65] Type 1 DM treatment relies on insulin 
replacement by self-injection, with doses adjusted on the basis of self-monitoring of blood 
glucose levels, in order to mimic the natural insulin fluctuation levels through the day.[66] 
Type 2 DM treatment focuses on delaying the progression of the disease via regulation of 
ingested food, physical exercise, weight management, and smoking cessation.[66-67] Oral and 
injectable medication such as the glucagon-like peptide-1 (GLP-1) are also recommendable to 
improve insulin production and function.[66, 68] However, the progression of the disease 
frequently ends up requiring insulin administration as well.[65] The therapeutic strategies 
currently used in DM treatment are, therefore, mostly based on the parenteral administration 
of drugs. Hence, pain and anxiety caused by daily injections, together with numerous 
associated adverse effects, including infections, insulin edema, local hypertrophy, 





































































compliance.[69] Here, we review the developing role of microfluidics in diabetes therapies, 
from diagnosis to management. 
 
3.3.1 Microfluidics in the Diagnosis of Diabetes 
Diabetes detection is most commonly made by blood glucose tests, however, irregular glucose 
levels are not a good indicator when it comes to early diagnosis of the disease.[70] It is urgent 
to find efficient methods for screening asymptomatic diabetes patients, and thereby reduce the 
subsequent physical, psychological, and economical burden. Several immune indicators are 
considered reliable for early diabetes detection, however, they require the use of complex test 
methods performed in relatively large facilities.[70] In 2012, Yao et al.[70] reported a cyber-
based telemedicine system for insulin quantification in an integrated PDMS micro-fluidic 
system for early detection of diabetes. With the use of two pneumatic micropumps and 
immune microbeads in a micromixer, the authors could target insulin for further 
quantification by chemiluminescent assays (Figure 8). The controlling of the platform via 
wireless allowed the remote monitoring of the performance of the device, data collection and 






































































Figure 8. Architecture of the microfluidic-based telemedicine system. The insulin detection 
was performed in a PDMS-based microfluidic system equipped with beads for insulin 
targeting, and further supported by electronics and communication hardware for exchanging 
the control parameters and the results with off-site specialists. Reprinted with permission.[70] 
© 2013, SAGE Publications. 
 
Yin et al.,[71] in 2016, reported an optical fiber sensor integrated microfluidic chip for 
ultrasensitive glucose detection. The device was based on a long-period grating (LPG) sensor 
fabricated in a small-diameter single-mode fiber (Figure 9). Poly (ethylenimine) (PEI) and 
poly (acrylic acid) (PAA) were added to the surface of the LPG sensor layer-by-layer, by self-
assembly, for support and signal enhancement. A negatively charged glucose oxidase layer 
was further immobilized on the outer layer for glucose sensing. The biosensor was then 
embedded into the microchannel of the chip. Results showed the efficient detection of 
ultralow concentrations of glucose, in a remarkably fast and low sample consumption 
manner.[71] 
 
Figure 9. a) Schematic design of the optical fiber biosensor integrated microfluidic chip: (1) 





































































mode coupling and optical resonance in the LPG biosensor; c) Working mechanism of the 
multilayer film for glucose sensing and signal enhancement. Reprinted with permission.[71] © 
2016, Optical Society of America. 
 
Type 1 DM is characterized by increased levels of autoantibodies against insulin, glutamic 
acid decarboxylase, and insulinoma associated protein‐ 2, among others, and their detection 
enables clinical diagnosis of the disease.[72] In 2017, aiming at early diagnosis and predictive 
screening of diabetes in order to allow for efficient disease management before the 
appearance of life-threatening symptoms, Duan et al.[73] created an enhanced suspension assay 
multiplexed in microfluidic channels. The authors designed a microfluidic array that 
generated individual porous droplets made of a polyethylene glycol (PEG) smart hydrogel, 
and with detection chemistries optimized for the target biomolecules (Figure 10a). For this 
purpose, droplet hydrogels were spatially arrayed in a microfluidic serpentine array for 
multiplexing. Flow switching was used to direct unwanted droplets to a waste channel, while 
redirecting the droplets to the traps when the correct detection chemistry was generated. Then, 
the microfluidic flow was used to push assay reagents to the substrate surface. After UV 
curing, porogen molecules were washed away by buffer perfusion, generating the porous 
hydrogel droplets (Figure 10b). The validation of the device was completed by the addition 
of target antibodies into the microchannels, which provided varying fluorescence intensities 






































































Figure 10. Quantitative microfluidic droplet array for diabetes detection. a) Individual 
droplets were generated with detection chemistries optimized for target molecules. The 
droplets were then spatially arrayed in designated traps within the serpentine channels. b) The 
serpentine microchannels allowed trapped droplets to be perfused by assay reagents. After UV 
curing, buffer perfusion was used to wash away the porogen molecules (yellow stripes), 
creating a porous hydrogel droplet. Target antibodies (blue) and reporter antibodies (green) 
were then introduced into the microchannels. c) The result of spatial multiplexing was an 
array of droplets targeting individual diabetes antibodies, illustrated on the top panel by the 
generation of multicolored droplets. In the actual assay (lower panel), only a single reporter 
wavelength was required, providing fluorescence intensities that varied at each spatial 
position per its respective antibody detection. Adapted with permission.[73] © 2017, WILEY–
VCH Verlag GmbH & Co. KGaA, Weinheim. 
 
Other examples of the most recent advances in the use of lab-on-chip technologies for the 
detection of diabetes can be found in Figure 11. Evans et al.[74] reported the development of a 
filter paper-based analytical device (µPAD) modified with silica nanoparticles. The µPAD 
improve the signal intensity and uniformity for clinically relevant enzymatic reactions, 





































































combining wax printing fabrication techniques with the basic principles of origami. The assay 
is based in multiple and simultaneous colorimetric assays, can accommodate one or more 
analytes, and has been successfully used to test blood glucose levels (Figure 11B).[75] 
Kugimiya et al.,[76] in turn, proposed a fluidic microchip biosensor for amino acid detection 
using enzymatic reactions coupled to spectrophotometric measurements of hydrogen 
peroxide.[76] Two microchips with two chemical inlets each, and a serpentine for reaction 
were connected in series under optimized temperature settings (Figure 11C). The analysis 
could be completed within 30 minutes. Interestingly, beyond the molecular biomarkers, DM 
detection has also been achieved by the analysis of the stability and deformability of 
erythrocytes.[77] For this reason, Zhan et al.[78] developed simple microfluidic tool for 
examining erythrocyte fragility based on the characterization of osmotic lysis kinetics under 
hydrodynamic focusing (Figure 11D).[78] The latter generates rapid dilution of the buffer and 
produces lysis of erythrocytes during their flow. The release of intracellular contents is 
monitored and quantified by their light intensity throughout the channel. 
 
Figure 11. Examples of microfluidic devices for diabetes detection applications. A) 
Illustration of a µPAD to test glucose with and without silica nanoparticles; B) Easy and low-





































































right image); C) A microfluidic biosensor for the detection of amino acids using enzymatic 
reactions coupled with spectrophotometric detection; D) A simple microfluidic tool for 
studying erythrocyte fragility by analyzing osmotic lysis kinetics under hydrodynamic 
focusing. Reprinted with permission 
(https://creativecommons.org/licenses/by/4.0/legalcode) .[74-78] 
 
Earlier this year, Furutani et al.[79] proposed a compact disc (CD)-shaped microfluidic device 
for multiple and rapid enzyme-linked immunosorbent assays (ELISA), which are widely used 
for the quantification of specific proteins. The device can perform the analysis of up to 15 
samples simultaneously within 16 minutes, and consists of six different layers containing the 
microchannels, the reagent reservoirs, and the parts for reaction.[79] Also very recently, 
Professor Vipul Bansal, Director of the Ian Potter NanoBioSensing Facility at the Royal 
Melbourne Institute of Technology, announced that researchers from the same institute have 
developed a cost-effective and simple-to-use detection kit based on a microchip and a sensor 
coated with nanoparticles, capable of detecting blood markers that indicate the early loss of 
beta cells.[80] Such pioneering study was done in collaboration with Dr. Ravi Shukla, and 
currently also with engineers at the Micro Nano Research Facility (MNRF), aiming at the 
miniaturization of the sensor into a microfluidic chip. The kit is expected to be implemented 
as a standard test for newborns, in order to diagnose the disease in its earliest stages.[80] 
 
3.3.2 Microfluidics in Diabetes Management 
While devoting a significant amount of resources and money towards the development of 
efficient diabetes detection strategies, researchers from all over the world have also been 
investing tremendous efforts towards the creation of advanced drug delivery systems and 
technologies that can help several millions of people sentenced to lifelong medication. As 





































































heart attack, stroke, and lower-limb amputations, among others.[81] A proper management of 
the disease is therefore extremely important, not only to ensure an adequate glycemic control, 
but also to prevent future complications.[82] 
The unprecedented advances of microfluidics have been expanding the amount of alternatives 
that can revolutionize diabetes management. Huang et al.[83] reported the development of a 
microfluidic system capable not only of measuring glucose concentrations in real-time, but 
also of automatically injecting insulin. This glucose sensing and insulin injection (GSII) chip 
was fabricated using micro-electro-mechanical-system (MEMS)-based technologies, 
comprising two modules: a PDMS-based microfluidic control module, including micropumps, 
microvalves and microchannels, and a sensing module, consisting of glucose sensing 
electrodes, a flow sensor (Figure 12).[83] With the GSII, 30-100 µL of sample were enough 
for an accurate determination of the glucose concentrations as low as 1.61 mM by the 
incorporated glucose sensor. Afterwards, precise amounts of insulin could be injected through 
a stick needle attached to a micropump while monitored by the flow sensor. 
 
Figure 12. Photograph of the GSII microfluidic system, composed of a PDMS-based 
microfludic control module (microchannels, micropumps and microvalves), and a sensing 
module (electrochemical glucose sensor and flow sensors). Reprinted with permission.[83] © 






































































The adequate monitoring of blood glucose levels is an essential part of managing diabetes.[82] 
Following the discovery that the whole-blood glycated hemoglobin, particularly the glycated 
hemoglobin A1c (HbA1c) is the best marker for long-term glycaemic control,[84] Lee et al. [85] 
proposed a microfluidic device for self-monitoring of both blood glucose and HbA1c. In this 
device, the loaded blood sample was absorbed in the PDMS microchannel due to its 
hydrophilic nature. The application of AC voltage on the dielectrophoretic (DEP) electrodes 
incorporated in the device attracted red blood cells, while plasma remained flowing, therefore 
separating the blood into two main components.[85] The plasma was driven to the detection 
zone by the use of micropumps and microvalves for glucose detection. Afterwards, distilled 
water was injected into the microchannel for red blood cell lysis, the DEP force was turned 
off, the microvalves of HbA1c were opened, and the cell lysates were transported into the 
HbA1c detection zone. This system encompasses both sample pre-treatment and sensing, 
and could be used by diabetic patients for self-monitoring of blood glucose and HbA1c 
levels in a quick and automatized manner.[85] 
As mentioned above, type 1 and type 2 DM therapies rely mostly on the use of injectable 
treatments that, for numerous reasons, suffer from low patient compliance.[86] Particularly, 
insulin subcutaneous injections are used as an attempt to replace the physiological insulin 
secretion, and dominate the popular perception of the life of a diabetic patient. Therefore, 
alternative routes of administration represent an important area of study. The use of advanced 
drug delivery systems such as micro- and nanoparticles has been demonstrating ground-
breaking solutions for this problem, particularly aiming at the oral and pulmonary routes of 
anti-diabetic drug administration.[64, 66, 87] In fact, the emergence of quantum effects of 
nanosized materials renders them with useful physical, chemical and biological properties.[10d, 
66] A wide variety of materials and production strategies have been applied in the development 





































































mucoadhesive and mucopenetrating polymers,[88] adsorption enhancers and enzymatic 
inhibitors,[89] pH-responsive platforms,[90] and targeted drug carriers,[91] among others. 
However, the high batch-to-batch variations, and the scale-up-related limitations of bulk 
production lead to unsatisfactory production rates, while microfluidic techniques are 
envisaged to overcome the restrained production of such promising drug delivery 
platforms.[10c] In 2015, Araújo et al.[89d] proposed the microfluidic preparation of GLP-1 and 
dipeptidyl peptidase-4 (DPP4) inhibitor loaded composites for diabetes therapy based on a 
flow-focusing geometry (Figure 13). The authors started by loading GLP-1 into poly(lactic-
co-glycolic acid) (PLGA) and porous silicon (PSi) nanoparticles, which were further coated 
with chitosan, for mucoadhesive purposes. Afterwards, cell penetrating peptides (CPPs) were 
conjugated to the chitosan, due to their ability to harmlessly enter the cells, with the aim to 
increase transcellular transport.[92] Then, glass-capillary microfluidic techniques were used to 
encapsulate the nanoparticles together with dipeptidyl peptidase 4 (DPP4) into an enteric 
polymer (hydroxypropyl methylcellulose acetyl succinate; HPMC-AS; Figure 13).[89d] The 
produced nanoparticles showed high encapsulation efficiency and, importantly, an exquisite 
degree of reproducibility due to the microfluidics technique used. These studies were 
supported by the succeeding in vivo tests performed by the same authors, in which the PLGA-
based particles were administered to a diabetic rat model.[89c] Results showed an increase in 
the hypoglycemic effects in a sustained and prolonged manner after the administration GLP-1 
loaded nanoparticles, supporting the successful development of an oral protein/peptide 






































































Figure 13. Schematic representation of a microfluidics glass capillary technique with a flow 
focusing geometry for the production a multifunctional drug delivery system for diabetes. The 
inner fluid consisted of GLP-1 loaded chitosan-coated PLGA or PSi nanoparticles in HPMC-
AS solution, where the enzymatic DPP4 inhibitor was also dissolved. The outer continuous 
fluid consisted of an aqueous solution (F127) for stabilization of the final particles. Reprinted 
with permission.[89d] © Creative Commons Attribution-NonCommercial 3.0 Unported Licence. 
 
3.3.3 Other Applications in Diabetes Therapy 
Since impaired glucose metabolism can lead to low-grade inflammation and activation of the 
innate immune system, diabetic patients have increased risk of cardiovascular 
complications.[93] For this reason, leukocyte enumeration if frequently assessed in diabetic 
patients, but it is urgent to identify cell-based biomarkers to quantify specific immune 
functions of these cells, beyond their counting.[94] In this sense, in 2016, Hou et al.[95] 
described the creation of a microfluidic system for a single-step, rapid, and label-free isolation 
of neutrophils, which are the key effector cells of the innate immune system. The authors used 





































































authors for size-based separation of diseased cells from the blood,[96] for neutrophil 
purification. The DFF device is a 10 cm long PDMS layer, and consists of a two-inlet and 
four-outlet spiral microdevice (Figure 14). With the use of Dean Forces, the neutrophils 
migrated to the outlets according to their size. After purification, the authors could evaluate 
their rolling behavior in E-selectin, which is a critical step in leukocyte recruitment during 
inflammation.[95] 
 
Figure 14. Schematic representation of the microfluidic chip for size-based separation of 
neutrophils, consisting of a two-inlet and four-outlet spiral PDMS microdevice. Adapted with 
permission (https://creativecommons.org/licenses/by/4.0/legalcode).[95] 
 
Blood glucose level is regulated by a set of endocrine hormones released by different cells, 
with the intestinal and pancreatic cells playing a crucial role in this process.[97] Whereas 
insulin secreting β-cells are located in the pancreas, small intestine L-cells are the responsible 
for stimulating its secretion. Taking advantage of the outstanding versatility of microfluidics, 
Nguyen et al.[97] proposed an endocrine system aiming at the screening of drugs for diabetes 
therapy by measuring insulin release over time. The authors used a microfluidic perfused 3D 
cell-culture chip for co-culturing intestinal and pancreatic cells, in order to manage the effect 
of glucose on the secretion of GLP-1 by the intestinal cells, and insulin from the pancreatic 





































































was used to produce a PDMS layer through soft lithography techniques. After plasma 
treatment, the PDMS layer was attached to a glass slide. Small metal tubes were used to 
connect the inlets and outlets to flexible polymeric tubes. The microfluidic channel was 
divided into a wide central cell culture compartment and two wide side channels by elliptical 
micropillars. Results showed that the GLP-1 producing cells stimulated insulin secretion by 
the pancreatic cells, as well as that higher glucose concentration levels in the media lead to 
faster and higher insulin secretion.[97] Importantly, the authors suggest that the ability to study 
dynamic profiles of insulin secretion can be used to effectively screen new drugs by 
evaluating their effects on insulin production.  
In the same line, Bauer et al.[98] developed a microfluidic two-organ-chip model, 
incorporating both pancreatic and liver cells.  The fabrication of the device was based on 
PDMS molding, in which two cell culture compartments were connected by a microchannel. 
An on-chip micropump was used to create a pulsatile flow. The microfluidic chip allowed for 
the in vitro evaluation of the physiological crosstalk between pancreatic islet microtissues and 
liver spheroids, and the authors could show that insulin secreted in the circulation by the 
pancreas stimulates the glucose uptake by the liver cells.[98] Also, absence of insulin in 
circulation led to an impaired glucose consumption by the liver. Likewise, a decrease in 
glucose concentration also compromised insulin secretion, suggesting a functional feedback 
loop between the two tissues. 
 
3.4. Other applications 
Recently, RNA interference through the delivery of small interfering RNAs (siRNAs) has 
revealed great potency in silencing gene expression in different pathologies; however, in spite 
of the great efficacy of the method itself, the translation into treatment is challenged by the 
lack of approaches to safely and efficiently deliver the nucleic acids to target cells.[99] 





































































but the method was still far from optimal for the synthesis of such nanosystems, since the 
resulting formulation was too diluted, with the formation of precipitate.[35] Moreover, further 
steps (e.g., sonication or dialysis) were still insufficient to produce particles homogeneous in 
size.[100] Thus, new engineering was urgently needed to achieve high-throughput screening 
synthesis of siRNA-loaded NPs. Chen et al.[101] developed a microfluidic system producing a 
library of 70 different lipid nanoparticles with a loading degree up to 80% of siRNAs through 
stepwise ethanol dilution. Following in vitro and in vivo gene silencing assays, the authors 
demonstrated the presence of a high rate of false negatives, up to 90%, highlighting the 
importance of the preliminary formulation screening in the development of nanosystems for 
siRNA encapsulation. 
By adapting a similar microfluidic device, Rungta et al.[102] synthetized lipid nanoparticles 
encapsulating siRNAs against GRIN1, the gene encoding the GluN1 subunit of the NMDA 
receptor (NMDAR). The authors then assessed whether the delivery of siRNAs by the lipid 
nanoparticles successfully manipulated the expression of proteins involved in neuronal 
processes in vitro and in vivo. The herringbone structure of the microfluidic micromixer 
resulted in the production of lipid nanoparticles presenting a diameter between 50 and 60 nm 
and encapsulating the desired siRNA. The transfection was successful and led to robust 
knockdown of GluN1 expression both in vitro and in vivo, as demonstrated by western blots 
and functional disruption of NMDAR synaptic currents. 
 
Other recent applications of microfluidics have been developed for the treatment of human 
immunodeficiency virus (HIV), acute liver failure (ALF) and inflammatory bowel disease 
(IBD). Indeed, Liu et al.[103] engineered a theranostic platform for ALF, a clinical syndrome 
resulting from the rapid loss in hepatocyte function, by using a glass capillary device. The 
microfluidic platform allowed the single-step co-encapsulation of porous silicon and gold 






































































Figure 15. Preparation and characterization of DPSi/DAu@AcDEX. A) Schematic 
illustration of the microfluidic platform used to prepare DPSi/DAu@AcDEX. B) TEM 
images of a) DPSi, b) DAu, c) AcDEX, d) DPSi@AcDEX and e,f) DPSi/DAu@AcDEX with 
respective EDX spectra witnessing successful encapsulation C) Size (nm), PdI, and surface 
zeta‐potential (mV) values at each synthesis step. D) FTIR spectra of PSi, DPSi, AcDEX, 





































































Reprinted with permission.[103] © 2017 WILEY–VCH Verlag GmbH & Co. KGaA, 
Weinheim 
 
A novel small drug molecule, XMU-MP-1, was loaded in the pores of the porous silicon 
nanoparticles, improving both the efficacy of the compound and its biological profile, 
reducing the side effects. The role of gold nanoparticles was to image the affected tissue by 
CT-imaging. However, both drug encapsulation and use of gold nanoparticles present 
challenges: in fact, the confinement of drug molecules into the pores of porous silicon, while 
preventing their release proves challenging. As for gold nanoparticles, they should be small to 
penetrate into the cells and enable imaging, but this size range is also resulting into rapid 
excretion from the body. Considering this, Liu et al. decided to encapsulate both the 
nanosystems into a polymeric matrix of AcDEX, to prevent their own intrinsic limitations. 
Since this polymer features pH responsive properties, both drug molecules and gold 
nanoparticles are released inside the cells upon degradation of the polymeric matrix at 
endocellular pH. Altogether, the results obtained showed that the produced nanocomposite is 
actually a potential theranostic platform for ALF.  
Another interesting platform produced single-step reassembling of high density lipoproteins 
(HDL) with antithrombotic effect, allowing also the simultaneous loading of simvastatin, gold, 
iron oxide NPs, quantum dots, or fluorophores, to produce a biocompatible theranostic 
platform.[104] 
Regarding the application in HIV, Martins et al.[105] prepared a brain targeted poly(lactic-co-
glycolic acid) (PLGA) nanosystem encapsulating Efavirenz (EFV) with both a conventional 






































































Figure 16. Schematic representation of both bulk and microfluidic methods for the 
preparation of EFV-loaded PLGA NPs. In both it occurs nanoprecipitation of a mixture of 
PLGA in DMSO (organic phase) into an aqueous phase, consisting of a solution of Tween®80. 
Reprinted with permission from.[105] © 2018, Elsevier B.V. 
 
The encapsulation of EFV in the system it is crucial for its biodistribution to the brain, since 
the drug is not able to pass the blood brain barrier (BBB). Compared to the conventional 
method, the nanoparticles prepared by nanoprecipitation in a glass capillary device with co-
flow geometry, resulted more efficient in encapsulating the drug (80.7% versus 32.7%) while 
being smaller in size (73 nm versus 133 nm). Since the particles produced by microfluidics 
exhibited better properties, Martins et al. continued their investigations only with those 
systems showing that they present a sustained release profile with only 50% of EFV released 
in 24h. Moreover, the final system, modified with a transferrin-receptor binding peptide, 
showed increased interaction with BBB cells and improved 1.3.-fold the permeability of the 
drug. 
Microfluidics platforms have been developed to engineer nanoparticles for the treatment of 





































































current therapies are directed exclusively to address the symptoms of the disease while being 
characterized by heavy systemic side effects; thus, nanomedicine can represent a valid 
alternative, aiming to address the delivery of those drugs exclusively in the site of 
inflammation. In a recent study, Li et al.[106] prepared a composite nanosystem to overcome 
the intrinsic limitations of the different materials, engineering the particles to complete their 
journey across the gastro-intestinal tract and finally reach their target site. The system was 
based on porous silicon nanoparticles functionalized with hyaluronic acid (HA) to achieve 
retention in the intestinal mucosa. The nanoparticles were then coated by hydroxypropyl 
methylcellulose acetate succinate (HPMCAS) LF type, to achieve gastro-protection and 
dissolution of the protective capsule in the intestine at pH 5.5. Budesonide (BUD) was 
encapsulated in the pores of the PSi nanoparticles, together with ascorbyl palmitate (AP): AP 
is a small molecule, which forms a gel and induces the enzyme-responsive release of the drug 
once the system reaches the target site and meets enzymes that are upregulated and released in 
inflamed tissue. Microfluidic technique came into play during the encapsulation step, 
allowing the easy coating with the gastro-protective polymer HPMCAS-LF (Figure 17). As 
presented in Figure 17d, the final system (BUDAP@PSi-HA@LF) looks highly 






































































Figure 17. a) Schematics of the synthesis of BUDAP@PSi-HA@LF. b,c) Transmission 
electron microscopy (TEM) image of PSi and PSi-HA, respectively. d) Confocal and SEM 
images showing the monodispersity of PSi-HA@LF and the successful encapsulation of PSi-
HA (green because conjugated with FITC) in LF (labelled with TRITC and thus red) through 
the resulting yellow color after overlaying red and green channels. Adapted with 
permission.[106] © 2018, Elsevier B.V. 
 
Moreover, the final system showed total recover of the transepithelial electrical resistance 
(TEER) in the in vitro IBD model, demonstrating together with the decrease of release of IL-8 
from cells that the composite NPs are able to induce a prolonged therapeutic effect. In vitro 
observations have been then confirmed by in vivo studies, which displayed mitigation of 
weight loss in colitis induced-animals treated with BUDAP@PSi-HA@LF, significant 
decrease of the disease activity index (DAI) and reduction of IL-1β and IL-6 levels. 





































































tissues were examined and scored, showing high reduction in disease severity of the sections 
belonging to tissue treated with BUDAP@PSi-HA@LF (Figure 18a). 
 
Figure 18. In vivo therapeutic efficacy of different BUD formulations on an IBD model of 
colitis induced in mice. a) H&E histology images of the distal end of colon after 7 d of 
treatment. b) Histopathology score of the distal end of colon after 7 d of treatment. Data are 
means ± SD (n = 5). *p < 0.05, **p < 0.01 and ***p < 0.001 versus the colitis group. Adapted 











































































Table 2. Summary of the applications of microfluidics in different diseases. 
Application Platform Summary of the Findings Ref. 
Cancer 
Glass capillary, various 
geometries; PDMS, 
various geometries 
Production of homogenous micro-and nanoparticles, co-loading 
of various drugs with different physicochemical properties, 
enhancement of the drug dissolution rate, combinatorial 
production of different formulations 
[6, 10a, 11a, 15b, 
32, 35, 38, 39b, 






Production of homogenous cancer vaccines, evaluation of 




Glass capillary, PDMS, 
Polymers, Paper 
Production of multicomposite formulations for the oral delivery of 
insulin, determination of glucose and insulin concentration, early 
diagnosis of diabetes, analysis of the neutrophils   
[70-71, 73-78, 83, 
88a, 89d] 
RNA Delivery Different platforms Successful encapsulation and enhanced delivery of RNA [101-102] 
Liver Failure Glass capillary 
Production of homogenous nanoparticles, co-encapsulation of 
imaging moieties, reduction in the drug side effects 
[103] 
Thrombosis PDMS 
Production of synthetic high density lipoproteins, with the 
simultaneous encapsulation of drug and theranostic moieities 
[104] 
HIV Glass capillary 






Production of multicomposite particles for the local delivery of 
drug, improved efficacy compared to the drug only 
[106, 108] 
 
4. Advantages, Disadvantages, and Industrial Application 
There is no doubt that nanomedicine has gained increasing interest over years. The possibility 
to easily tune particle size, shape and functionalization represent the key factor making drug 
delivery systems attractive tools for the treatment of different pathologies.[109] However, 
despite the general enthusiasm spreading all over the world and the high innovation reached 
during the years, the translation of nanoparticles into clinic still represent a great challenge. At 
the base of this failure is the current lack of fabrication methodologies to control 
nanoparticles’ properties (especially size and homogeneity in size), batch-to-batch 
reproducibility, and large-scale production. All these factors tremendously affect the 
translation into clinic, together with the inadequacy and/or absence of tools for rapid 
nanoparticles screening and platforms for in vitro testing, able to mimic a complex and 
dynamic system as the human body and guarantee good in vitro-in vivo correlations.[6, 40] 
In this scenario, microfluidics offers a solution to the limitations imposed by bulk fabrication 





































































distribution and high encapsulation efficiency. Moreover, the technique offer advantageous 
reduction of reagents consumption due to the miniaturization of the process, which turns out 
to be very efficient.[10a] 
Another benefit offered by microfluidics is the possibility to build up libraries of 
nanoparticles in a very easy way. Valencia et al.[50] indeed, synthetized a library of 45 
different nanoparticles, by combining 15 different precursors in different ratios in a 
microfluidic integrated platform, meanwhile Wang et al.[110] were able to obtain 648 
nanocarriers within just 2.5 hours by using a system able to sample, dilute, meter and mix 
different precursors in an automated way. The possibility to build up nanoparticles libraries in 
such a fast and easy way represents a great advantage in the nanoparticles’ optimization 
process. In fact, when fabricating nanoparticles different features should be taken into account, 
like composition, size, charge, shape, softness and drug loading and thus, the optimization 
process is very time consuming and represents a challenge for conventional fabrication 
methods. The possibility to integrate the microfluidic device with a multi-inlet micromixer 
enables to mix different precursors before nanoprecipitation. Moreover, different parameters, 
like geometry of the device, polarity of the solvents, flow rates, concentration and 
composition of the precursors, can be tuned in order to obtain particles with specific 
characteristics.[6] 
Another advantage provided by microfluidics is the ability to produce nanoparticles in a 
highly reproducible manner. The fact that the entire process in automated and regulated by 
pumps operating in a continue flow regimen, drops dramatically the possibility to have batch-
to batch variations.[111] Moreover, the recent employment of a coaxial turbulent jet mixer by 
Valencia et al.[111b] allowed to produce nanoparticles up to 3 kg per day, showing that 
microfluidics it is also easy to scale-up and thus, appropriate for industrial scale production. 
Despite that, there are still some drawbacks to face in order to have a total translation of 





































































preparation it is not easy. The most common used, PDMS, is easy to manipulate and engineer 
in more complex channels structures, cheap and optically transparent.[11b] However, this 
material is sensitive to organic solvents, acids and bases, giving phenomena of swelling and 
degradation and has the tendency to absorb small molecules on its surface.[112] Moreover, it 
needs to be manipulated in clean room. Other options could be silicon or glass. Silicon has a 
very good chemical compatibility range and it is thermostable,[113] but it is very expensive, 
fragile and opaque to visible and ultraviolet light.[11b] Glass has several advantages; it is cheap, 
rigid, optically transparent, chemically inert, resistant to high temperatures and easy to 
modify.[113] However, it is difficult to handle and does not allow the construction of complex 
structures. Moreover, it requires production in clean room in some cases.[114]  Altogether, it is 
difficult to choose the right material to build up a chip for nanoparticle fabrication, since all of 
them present different intrinsic challenges. In addition, the fabrication should be performed in 
dedicated microfabrication facilities and it requires specific equipment and personnel with 
particular skills. Finally, it should be also considered that complex designs are often required 
for parallelization, which is important to achieve large-scale production.[6] 
In overall, microfluidics holds great promises in the translation of nanomedicine into clinic 
and industrial production. The possibility to produce different types of nanocarriers at 
industrial scale, with very low batch-to-batch variations makes microfluidics a versatile and 
attractive alternative to conventional fabrication methods. The fast and constant advance of 
both microfluidics and material science will bring solutions to overcome the production 
challenges in a not too distant future. 
 
5. Conclusions 
This review focuses on the applications of a wide variety of microfluidic devices reported in 
the literature both as platforms for the preparation of advanced biomaterials and as sensors. 





































































sophistication holds the promise of revolutionizing the current challenges of cancer, 
immunotherapy, and diabetes therapy. The exquisite control over the miniaturized materials 
and platforms, the increased batch-to-batch reproducibility, and the possibility for large-scale 
production have already shed a light on the microfluidics exciting opportunities in 
potentiating the clinical translation of nanotechnology-based therapies. The acceptance and 
effective translation of the technique awaits now for the joint efforts between researchers of 
different fields, from biologists to engineers, the pharmaceutical industries, and clinicians to 
become a reality.  
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4704580), the Helsinki Institute of Life Science, and Academy of Finland (decision no. 
1317042). 
 
Received: ((will be filled in by the editorial staff)) 
Revised: ((will be filled in by the editorial staff)) 
Published online: ((will be filled in by the editorial staff)) 
 
References 
[1] O. C. Farokhzad, R. Langer, ACS nano 2009, 3, 16. 
[2] K. Park, J Controlled Release 2007, 120, 1. 
[3] a) E. K. Wujcik, C. N. Monty, Wiley Interdisciplinary Reviews: Nanomedicine and 
Nanobiotechnology 2013, 5, 233; b) G. G. Wallace, M. J. Higgins, S. E. Moulton, C. Wang, 
Nanoscale 2012, 4, 4327; c) S. Lavenus, G. Louarn, P. Layrolle, Int J Biomater 2010, 2010; 
d) P. A. Tran, L. Sarin, R. H. Hurt, T. J. Webster, J Mater Chem 2009, 19, 2653. 
[4] R. Juliano, Nat Rev Drug Discovery 2013, 12, 171. 
[5] V. J. Venditto, F. C. Szoka, Adv Drug Deliv Rev 2013, 65, 80. 
[6] D. Liu, H. Zhang, F. Fontana, J. T. Hirvonen, H. A. Santos, Adv Drug Deliv Rev 2018, 
128, 54. 
[7] João P. Conde, N. Madaboosi, Ruben R. Soares, J. T. S. Fernandes, P. Novo, G. 
Moulas, V. Chu, Essays Biochem 2016, 60, 121. 
[8] E. Rune,  US2566443A, 1951. 
[9] D. C. Duffy, J. C. McDonald, O. J. A. Schueller, G. M. Whitesides, Anal Chem 1998, 
70, 4974. 
[10] a) D. Liu, H. Zhang, F. Fontana, J. T. Hirvonen, H. A. Santos, Lab Chip 2017, 17, 
1856; b) I. U. Khan, C. A. Serra, N. Anton, T. F. Vandamme, Expert opinion on drug delivery 
2015, 12, 547; c) J. P. Martins, G. Torrieri, H. A. Santos, Expert opinion on drug delivery 
2018, 15, 469; d) S. Ding, N. Anton, T. F. Vandamme, C. A. Serra, Expert opinion on drug 





































































[11] a) F. Fontana, M. P. Ferreira, A. Correia, J. Hirvonen, H. A. Santos, J Drug Delivery 
Sci 
Technol 2016, 34, 76; b) G. M. Whitesides, Nature 2006, 442, 368; c) W. K. Coltro, S. M. 
Lunte, E. Carrilho, Electrophoresis 2008, 29, 4928; d) B. Ziaie, A. Baldi, M. Lei, Y. Gu, R. A. 
Siegel, Adv Drug Deliv Rev 2004, 56, 145. 
[12] a) S. Wang, T. Chinnasamy, M. A. Lifson, F. Inci, U. Demirci, Trends Biotechnol 
2016, 34, 909; b) R. Verma, R. R. Adhikary, R. Banerjee, Lab Chip 2016, 16, 1978. 
[13] a) G. T. Vladisavljevic, N. Khalid, M. A. Neves, T. Kuroiwa, M. Nakajima, K. 
Uemura, S. Ichikawa, I. Kobayashi, Adv Drug Deliv Rev 2013, 65, 1626; b) K. Domansky, J. 
D. Sliz, N. Wen, C. Hinojosa, G. Thompson, J. P. Fraser, T. Hamkins-Indik, G. A. Hamilton, 
D. Levner, D. E. J. M. Ingber, Nanofluidics, J Microfluidics Nanofluidics 
 2017, 21, 107. 
[14] A. Utada, L.-Y. Chu, A. Fernandez-Nieves, D. Link, C. Holtze, D. Weitz, Mrs 
Bullettin 2007, 32, 702. 
[15] a) T. Kawakatsu, Y. Kikuchi, M. Nakajima, J Am Oil Chem Soc 1997, 74, 317; b) I. 
Kobayashi, M. Nakajima, K. Chun, Y. Kikuchi, H. Fujita, AIChE Journal 2002, 48, 1639. 
[16] a) J. Zhou, A. V. Ellis, N. H. Voelcker, Electrophoresis 2010, 31, 2; b) H. Zhang, M. 
Chiao, J Med Biol Eng 2015, 35, 143; c) Y. Xia, G. M. Whitesides, Angew Chem Int Ed Engl 
1998, 37, 550. 
[17] a) T. Nisisako, T. Torii, T. Higuchi, Chem Eng J 2004, 101, 23; b) J. Plaza, M. Lopez, 
A. Moreno, M. Duch, C. Cané, Sens Actuators A 2003, 105, 305; c) C.-H. Lin, G.-B. Lee, Y.-
H. Lin, G.-L. Chang, J Micromech Microeng 2001, 11, 726; d) S. Okushima, T. Nisisako, T. 
Torii, T. Higuchi, Langmuir 2004, 20, 9905; e) T. Nisisako, T. Ando, T. Hatsuzawa, Lab Chip 
2012, 12, 3426. 
[18] a) R. K. Jena, C. Yue, Y. Lam, J Microsystem technologies 2012, 18, 159; b) P. S. 
Nunes, P. D. Ohlsson, O. Ordeig, J. P. Kutter, Microfluid Nanofluid 2010, 9, 145. 
[19] a) Z. Nie, S. Xu, M. Seo, P. C. Lewis, E. Kumacheva, J Am Chem Soc 2005, 127, 
8058; b) T. Thorsen, R. W. Roberts, F. H. Arnold, S. R. Quake, Phys Rev Lett 2001, 86, 4163. 
[20] a) T. Eusner, M. Hale, D. E. Hardt, J Manufacturing Sci Engineering 2010, 132, 
030920; b) H. Liu, M. Nakajima, T. Nishi, T. Kimura, Eur J Lipid Sci Technol 2005, 107, 
481; c) T. Nisisako, T. Torii, T. Higuchi, Lab Chip 2002, 2, 24; d) Y. Morimoto, W.-h. Tan, 
Y. Tsuda, S. Takeuchi, Lab Chip 2009, 9, 2217. 
[21] J. Tong, M. Nakajima, H. Nabetani, Y. Kikuchi, Y. Maruta, J Colloid Interface Sci 
2001, 237, 239. 
[22] a) A. Utada, E. Lorenceau, D. Link, P. Kaplan, H. Stone, D. Weitz, Science 2005, 308, 
537; b) R. K. Shah, H. C. Shum, A. C. Rowat, D. Lee, J. J. Agresti, A. S. Utada, L.-Y. Chu, 
J.-W. Kim, A. Fernandez-Nieves, C. J. Martinez, Mater Today 2008, 11, 18. 
[23] B. Herranz-Blanco, E. Ginestar, H. Zhang, J. Hirvonen, H. A. Santos, Int J Pharm 
2017, 516, 100. 
[24] a) T. Akyazi, L. Basabe-Desmonts, F. Benito-Lopez, Anal Chim Acta 2018, 1001, 1; 
b) C. Park, Y. D. Han, H. V. Kim, J. Lee, H. C. Yoon, S. Park, Lab Chip 2018, 18, 1533; c) M. 
Yang, W. Zhang, J. Yang, B. Hu, F. Cao, W. Zheng, Y. Chen, X. J. S. A. Jiang,  2017, 3, 
eaao4862. 
[25] E. K. Sackmann, A. L. Fulton, D. J. Beebe, Nature 2014, 507, 181. 
[26] P. Zhu, L. Wang, Lab Chip 2016, 17, 34. 
[27] J. T. Wang, J. Wang, J. J. Han, Small 2011, 7, 1728. 
[28] a) C. Kantak, S. Beyer, L. Yobas, T. Bansal, D. J. L. o. a. C. Trau,  2011, 11, 1030; b) 
C. Priest, A. Quinn, A. Postma, A. N. Zelikin, J. Ralston, F. Caruso, Lab Chip 2008, 8, 2182. 
[29] a) D. Dendukuri, D. C. Pregibon, J. Collins, T. A. Hatton, P. S. Doyle, Nat Mater 2006, 
5, 365; b) J. A. Champion, Y. K. Katare, S. Mitragotri, J Control Release 2007, 121, 3. 





































































[31] a) W. S. Saad, R. K. J. N. T. Prud’homme,  2016, 11, 212; b) E. Lepeltier, C. 
Bourgaux, P. Couvreur, Adv Drug Deliv Rev 2014, 71, 86. 
[32] R. Karnik, F. Gu, P. Basto, C. Cannizzaro, L. Dean, W. Kyei-Manu, R. Langer, O. C. 
Farokhzad, Nano Lett 2008, 8, 2906. 
[33] M. Lu, A. Ozcelik, C. L. Grigsby, Y. Zhao, F. Guo, K. W. Leong, T. J. Huang, Nano 
Today 2016, 11, 778. 
[34] a) J. B. Knight, A. Vishwanath, J. P. Brody, R. H. Austin, Phys Rev Lett 1998, 80, 
3863; b) E. Dashtimoghadam, H. Mirzadeh, F. A. Taromi, B. J. P. Nyström, Polymer 2013, 
54, 4972. 
[35] M. Rhee, P. M. Valencia, M. I. Rodriguez, R. Langer, O. C. Farokhzad, R. Karnik, 
Adv Mater 2011, 23, H79. 
[36] R. R. Hood, D. L. DeVoe, J. Atencia, W. N. Vreeland, D. M. Omiatek, Lab Chip 2014, 
14, 2403. 
[37] D. Liu, S. Cito, Y. Zhang, C. F. Wang, T. M. Sikanen, H. A. Santos, Adv Mater 2015, 
27, 2298. 
[38] D. Liu, H. Zhang, S. Cito, J. Fan, E. Makila, J. Salonen, J. Hirvonen, T. M. Sikanen, D. 
A. Weitz, H. A. Santos, Nano Lett 2017, 17, 606. 
[39] a) J. D. Tice, A. D. Lyon, R. F. Ismagilov, Anal Chem Acta 2004, 507, 73; b) P. M. 
Valencia, P. A. Basto, L. Zhang, M. Rhee, R. Langer, O. C. Farokhzad, R. Karnik, ACS nano 
2010, 4, 1671; c) L. Capretto, W. Cheng, D. Carugo, O. L. Katsamenis, M. Hill, X. Zhang, 
Nanotechnology 2012, 23, 375602; d) L. Capretto, D. Carugo, W. Cheng, M. Hill, X. Zhang, 
J Colloid Interface Sci 2011, 357, 243. 
[40] P. M. Valencia, O. C. Farokhzad, R. Karnik, R. Langer, Nat Nanotech 2012, 7, 623. 
[41] R. L. Siegel, K. D. Miller, A. Jemal, CA Cancer J Clin 2017, 67, 7. 
[42] a) A. Wicki, D. Witzigmann, V. Balasubramanian, J. Huwyler, J Control Release 2015, 
200, 138; b) D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, R. Langer, Nat 
Nanotech 2007, 2, 751; c) D. Bobo, K. J. Robinson, J. Islam, K. J. Thurecht, S. R. Corrie, 
Pharm Res 2016, 33, 2373. 
[43] X. Xu, W. Ho, X. Zhang, N. Bertrand, O. Farokhzad, Trends Mol Med 2015, 21, 223. 
[44] S. Wilhelm, A. J. Tavares, Q. Dai, S. Ohta, J. Audet, H. F. Dvorak, W. C. Chan, Nat 
Rev Mater 2016, 1, 16014. 
[45] J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, Nat Rev Cancer 2017, 17, 20. 
[46] a) T. Baby, Y. Liu, A. P. Middelberg, C.-X. J. C. E. S. Zhao, Chem Eng Sci 2017, 169, 
128; b) J. M. Lim, N. Bertrand, P. M. Valencia, M. Rhee, R. Langer, S. Jon, O. C. Farokhzad, 
R. Karnik, Nanomedicine 2014, 10, 401. 
[47] a) D. Liu, H. Zhang, E. Makila, J. Fan, B. Herranz-Blanco, C. F. Wang, R. Rosa, A. J. 
Ribeiro, J. Salonen, J. Hirvonen, H. A. Santos, Biomaterials 2015, 39, 249; b) B. Herranz‐
Blanco, D. Liu, E. Mäkilä, M. A. Shahbazi, E. Ginestar, H. Zhang, V. Aseyev, V. 
Balasubramanian, J. Salonen, J. Hirvonen, Adv Funct Mater 2015, 25, 1488; c) D. Liu, C. R. 
Bernuz, J. Fan, W. Li, A. Correia, J. Hirvonen, H. A. Santos, Adv Funct Mater 2017, 27, 
1604508. 
[48] R. Wu, H. Zhang, J. Pan, H. Zhu, Y. Ma, W. Cui, H. A. Santos, G. Pan, Adv Mater 
Interfaces 2016, 3, 1600472. 
[49] H. Zhang, D. Liu, L. Wang, Z. Liu, R. Wu, A. Janoniene, M. Ma, G. Pan, L. 
Baranauskiene, L. Zhang, W. Cui, V. Petrikaite, D. Matulis, H. Zhao, J. Pan, H. A. Santos, 
Adv Healthc Mater 2017, 6. 
[50] P. M. Valencia, E. M. Pridgen, M. Rhee, R. Langer, O. C. Farokhzad, R. Karnik, ACS 
nano 2013, 7, 10671. 






































































[52] M. M. Hasani-Sadrabadi, E. Dashtimoghadam, G. Bahlakeh, F. S. Majedi, H. Keshvari, 
J. J. Van Dersarl, A. Bertsch, A. Panahifar, P. Renaud, L. Tayebi, M. Mahmoudi, K. I. Jacob, 
Nanomedicine (Lond) 2015, 10, 3431. 
[53] F. S. Majedi, M. M. Hasani‐Sadrabadi, J. J. VanDersarl, N. Mokarram, S. Hojjati‐
Emami, E. Dashtimoghadam, S. Bonakdar, M. A. Shokrgozar, A. Bertsch, P. Renaud, Adv 
Funct Mater 2014, 24, 432. 
[54] M. M. Hasani-Sadrabadi, S. Taranejoo, E. Dashtimoghadam, G. Bahlakeh, F. S. 
Majedi, J. J. VanDersarl, M. Janmaleki, F. Sharifi, A. Bertsch, K. Hourigan, L. Tayebi, P. 
Renaud, K. I. Jacob, Adv Mater 2016, 28, 4134. 
[55] M. R. Carvalho, D. Lima, R. L. Reis, V. M. Correlo, J. M. Oliveira, Trends Biotechnol 
2015, 33, 667. 
[56] J. W. Song, S. P. Cavnar, A. C. Walker, K. E. Luker, M. Gupta, Y. C. Tung, G. D. 
Luker, S. Takayama, PLoS One 2009, 4, e5756. 
[57] W. Zhang, W. Y. Lee, D. S. Siegel, P. Tolias, J. Zilberberg, Tissue Eng Part C 
Methods 2014, 20, 663. 
[58] F. Fontana, P. Figueiredo, T. Bauleth‐Ramos, A. Correia, H. A. Santos, Small 
Methods 2018, 2, 1700347. 
[59] F. Fontana, M. A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen, J. T. Hirvonen, 
H. A. Santos, Adv Mater 2017, 29, 1603239. 
[60] A. Boussommier-Calleja, R. Li, M. B. Chen, S. C. Wong, R. D. Kamm, Trends 
Cancer 2016, 2, 6. 
[61] E. Agliari, E. Biselli, A. De Ninno, G. Schiavoni, L. Gabriele, A. Gerardino, F. Mattei, 
A. Barra, L. Businaro, Sci Rep 2014, 4, 6639. 
[62] E. Vacchelli, Y. Ma, E. E. Baracco, A. Sistigu, D. P. Enot, F. Pietrocola, H. Yang, S. 
Adjemian, K. Chaba, M. Semeraro, M. Signore, A. De Ninno, V. Lucarini, F. Peschiaroli, L. 
Businaro, A. Gerardino, G. Manic, T. Ulas, P. Gunther, J. L. Schultze, O. Kepp, G. Stoll, C. 
Lefebvre, C. Mulot, F. Castoldi, S. Rusakiewicz, S. Ladoire, L. Apetoh, J. M. Bravo-San 
Pedro, M. Lucattelli, C. Delarasse, V. Boige, M. Ducreux, S. Delaloge, C. Borg, F. Andre, G. 
Schiavoni, I. Vitale, P. Laurent-Puig, F. Mattei, L. Zitvogel, G. Kroemer, Science 2015, 350, 
972. 
[63] L. J. Raffel, M. O. Goodarzi, in Reference Module in Biomedical Sciences, Elsevier,  
2014. 
[64] G. Sharma, A. R. Sharma, J.-S. Nam, G. P. C. Doss, S.-S. Lee, C. Chakraborty, J 
Nanobiotechnol 2015, 13, 74. 
[65] A. American Diabetes, Diabetes Care 2009, 32, S62. 
[66] O. Veiseh, B. C. Tang, K. A. Whitehead, D. G. Anderson, R. Langer, Nat Rev Drug 
discovery 2015, 14, 45. 
[67] S. Chong, D. Ding, R. Byun, E. Comino, A. Bauman, B. Jalaludin, Diabetes 
Spectrum : A Publication of the American Diabetes Association 2017, 30, 43. 
[68] F. Araujo, P. Fonte, H. A. Santos, B. Sarmento, Journal of diabetes science and 
technology 2012, 6, 1486. 
[69] T. A. Sonia, C. P. Sharma,  (Eds: T. A. Sonia, C. P. Sharma), Woodhead Publishing,  
2014, 59. 
[70] P. Yao, S. Tung, Z. Zhan, J. Hua, Z. Dong, Transactions of the Institute of 
Measurement and Control 2012, 35, 893. 
[71] M.-j. Yin, B. Huang, S. Gao, A. P. Zhang, X. Ye, Biomedical Optics Express 2016, 7, 
2067. 
[72] a) Z. Zhao, D. Miao, A. Michels, A. Steck, F. Dong, M. Rewers, L. Yu, Journal of 
immunological methods 2016, 430, 28; b) B. Zhang, R. B. Kumar, H. Dai, B. J. Feldman, 
Nature medicine 2014, 20, 948. 





































































[74] E. Evans, E. F. Moreira Gabriel, T. E. Benavidez, W. K. Tomazelli Coltro, C. D. 
Garcia, Analyst 2014, 139, 5560. 
[75] D. Sechi, B. Greer, J. Johnson, N. Hashemi, Anal Chem 2013, 85, 10733. 
[76] A. Kugimiya, E. Matsuzaki, Appl Biochem Biotechnol 2014, 174, 2527. 
[77] J. Wu, M. Dong, C. Rigatto, Y. Liu, F. Lin, npj Digital Medicine 2018, 1, 7. 
[78] Y. Zhan, D. N. Loufakis, N. Bao, C. Lu, Lab Chip 2012, 12, 5063. 
[79] S. Furutani, K. Nishio, N. Naruishi, Y. Akazawa-Ogawa, Y. Hagihara, Y. Yoshida, H. 
Nagai, Analytical sciences : the international journal of the Japan Society for Analytical 
Chemistry 2018, 34, 379. 
[80] G. Kaszubska, Vol. 2018, https://www.rmit.edu.au/news/all-
news/2018/jul/technology-early-detection-diabetes 2018. 
[81] D. Wild, R. von Maltzahn, E. Brohan, T. Christensen, P. Clauson, L. Gonder-
Frederick, Patient Education and Counseling 2007, 68, 10. 
[82] S. R. Shrivastava, P. S. Shrivastava, J. Ramasamy, J Diabetes Metab Disord 2013, 12, 
14. 
[83] C.-J. Huang, Y.-H. Chen, C.-H. Wang, T.-C. Chou, G.-B. Lee, Sens Actuators B 2007, 
122, 461. 
[84] a) A. D. Association, Diabetes Care 2009, 32 Suppl 1, S13; b) S. Ferri, S. Kim, W. 
Tsugawa, K. Sode, Journal of diabetes science and technology 2009, 3, 585. 
[85] T. Lee, C. Lin, C. Wu, G. Lee, "An integrated microfluidic system for rapid HbA1c 
and glucose measurement", presented at 2013 Transducers & Eurosensors XXVII: The 17th 
International Conference on Solid-State Sensors, Actuators and Microsystems 
(TRANSDUCERS & EUROSENSORS XXVII), 16-20 June 2013, 2013. 
[86] D. F. Kruger, S. LaRue, P. Estepa, Diabetes, Metab Syndr Obes: Targets Ther 2015, 8, 
49. 
[87] C. Y. Wong, H. Al-Salami, C. R. Dass, J Controlled Release 2017, 264, 247. 
[88] a) Y. Zhang, W. Wei, P. Lv, L. Wang, G. Ma, European journal of pharmaceutics and 
biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische 
Verfahrenstechnik e.V 2011, 77, 11; b) K. Netsomboon, A. Bernkop-Schnurch, European 
journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur 
Pharmazeutische Verfahrenstechnik e.V 2016, 98, 76; c) T. A. Sonia, C. P. Sharma, Journal 
of biomaterials applications 2013, 28, 62. 
[89] a) N. Shrestha, M.-A. Shahbazi, F. Araújo, E. Mäkilä, J. Raula, E. I. Kauppinen, J. 
Salonen, B. Sarmento, J. Hirvonen, H. A. Santos, Biomaterials 2015, 68, 9; b) N. Shrestha, F. 
Araujo, M. A. Shahbazi, E. Makila, M. J. Gomes, M. Airavaara, E. I. Kauppinen, J. Raula, J. 
Salonen, J. Hirvonen, B. Sarmento, H. A. Santos, J Control Release 2016, 232, 113; c) F. 
Araujo, N. Shrestha, M. J. Gomes, B. Herranz-Blanco, D. Liu, J. J. Hirvonen, P. L. Granja, H. 
A. Santos, B. Sarmento, Nanoscale 2016, 8, 10706; d) F. Araujo, N. Shrestha, M. A. Shahbazi, 
D. Liu, B. Herranz-Blanco, E. M. Makila, J. J. Salonen, J. T. Hirvonen, P. L. Granja, B. 
Sarmento, H. A. Santos, ACS nano 2015, 9, 8291. 
[90] a) K. Sonaje, Y. J. Chen, H. L. Chen, S. P. Wey, J. H. Juang, H. N. Nguyen, C. W. 
Hsu, K. J. Lin, H. W. Sung, Biomaterials 2010, 31, 3384; b) P. Mukhopadhyay, S. 
Chakraborty, S. Bhattacharya, R. Mishra, P. P. Kundu, International journal of biological 
macromolecules 2015, 72, 640. 
[91] a) E. Roger, S. Kalscheuer, A. Kirtane, B. R. Guru, A. E. Grill, J. Whittum-Hudson, J. 
Panyam, Molecular pharmaceutics 2012, 9, 2103; b) Y. Jin, Y. Song, X. Zhu, D. Zhou, C. 
Chen, Z. Zhang, Y. Huang, Biomaterials 2012, 33, 1573; c) J. P. Martins, R. D'Auria, D. Liu, 
F. Fontana, M. P. A. Ferreira, A. Correia, M. Kemell, K. Moslova, E. Mäkilä, J. Salonen, L. 
Casettari, J. Hirvonen, B. Sarmento, H. A. Santos, Small 2018, 14, 1800462. 






































































[93] a) J. C. Pickup, Diabetes Care 2004, 27, 813; b) G. Silbernagel, M. E. Kleber, T. B. 
Grammer, B. R. Winkelmann, B. O. Boehm, W. Marz, Diabetes Care 2011, 34, 2471. 
[94] a) F. Cavalot, P. Massucco, P. Perna, M. Traversa, G. Anfossi, M. Trovati, Diabetes 
Care 2002, 25, 2354; b) B. Menart-Houtermans, R. Rutter, B. Nowotny, J. Rosenbauer, C. 
Koliaki, S. Kahl, M. C. Simon, J. Szendroedi, N. C. Schloot, M. Roden, Diabetes Care 2014, 
37, 2326. 
[95] H. W. Hou, C. Petchakup, H. M. Tay, Z. Y. Tam, R. Dalan, D. E. K. Chew, K. H. H. 
Li, B. O. Boehm, Sci Rep 2016, 6, 29410. 
[96] a) H. W. Hou, R. P. Bhattacharyya, D. T. Hung, J. Han, Lab Chip 2015, 15, 2297; b) 
H. W. Hou, M. E. Warkiani, B. L. Khoo, Z. R. Li, R. A. Soo, D. S.-W. Tan, W.-T. Lim, J. 
Han, A. A. S. Bhagat, C. T. Lim, Sci Rep 2013, 3, 1259. 
[97] D. T. Nguyen, D. van Noort, I. K. Jeong, S. Park, Biofabrication 2017, 9, 015021. 
[98] S. Bauer, C. Wennberg Huldt, K. P. Kanebratt, I. Durieux, D. Gunne, S. Andersson, L. 
Ewart, W. G. Haynes, I. Maschmeyer, A. Winter, C. Ämmälä, U. Marx, T. B. Andersson, Sci 
Rep 2017, 7, 14620. 
[99] K. Whitehead, R. Langer, D. G Anderson, Whitehead, K.A., Langer, R. & Anderson, 
D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. 8, 129-138, Vol. 8,  
2009. 
[100] a) C. G. Koh, X. Zhang, S. Liu, S. Golan, B. Yu, X. Yang, J. Guan, Y. Jin, Y. Talmon, 
N. Muthusamy, K. K. Chan, J. C. Byrd, R. J. Lee, G. Marcucci, L. J. Lee, J Controlled 
Release 2010, 141, 62; b) B. Yu, J. Zhu, W. Xue, Y. Wu, X. Huang, L. J. Lee, R. J. Lee, 
Anticancer research 2011, 31, 771. 
[101] D. Chen, K. T. Love, Y. Chen, A. A. Eltoukhy, C. Kastrup, G. Sahay, A. Jeon, Y. 
Dong, K. A. Whitehead, D. G. Anderson, J Am Chem Soc 2012, 134, 6948. 
[102] R. L. Rungta, H. B. Choi, P. J. C. Lin, R. W. Y. Ko, D. Ashby, J. Nair, M. Manoharan, 
P. R. Cullis, B. A. MacVicar, Mol Ther Nucleic Acids 2013, 2, e136. 
[103] Z. Liu, Y. Li, W. Li, C. Xiao, D. Liu, C. Dong, M. Zhang, E. Mäkilä, M. Kemell, J. 
Salonen, J. T. Hirvonen, H. Zhang, D. Zhou, X. Deng, H. A. Santos, Adv Mater 2018, 30, 
1703393. 
[104] Y. Kim, F. Fay, D. P. Cormode, B. L. Sanchez-Gaytan, J. Tang, E. J. Hennessy, M. 
Ma, K. Moore, O. C. Farokhzad, E. A. Fisher, W. J. Mulder, R. Langer, Z. A. Fayad, ACS 
nano 2013, 7, 9975. 
[105] C. Martins, F. Araújo, M. J. Gomes, C. Fernandes, R. Nunes, W. Li, H. A. Santos, F. 
Borges, B. Sarmento, European journal of pharmaceutics and biopharmaceutics : official 
journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 2018. 
[106] W. Li, Y. Li, Z. Liu, N. Kerdsakundee, M. Zhang, F. Zhang, X. Liu, T. Bauleth-
Ramos, W. Lian, E. Mäkilä, M. Kemell, Y. Ding, B. Sarmento, R. Wiwattanapatapee, J. 
Salonen, H. Zhang, J. T. Hirvonen, D. Liu, X. Deng, H. A. Santos, Biomaterials 2018, 185, 
322. 
[107] F. Kong, X. Zhang, H. Zhang, X. Qu, D. Chen, M. Servos, E. Mäkilä, J. Salonen, H. A. 
Santos, M. Hai, D. A. Weitz,  2015, 25, 3330. 
[108] S. Bertoni, Z. Liu, A. Correia, J. P. Martins, A. Rahikkala, F. Fontana, M. Kemell, D. 
Liu, B. Albertini, N. J. A. F. M. Passerini,  2018, 1806175. 
[109] J. Shi, A. R. Votruba, O. C. Farokhzad, R. Langer, Nano Lett 2010, 10, 3223. 
[110] H. Wang, K. Liu, K.-J. Chen, Y. Lu, S. Wang, W.-Y. Lin, F. Guo, K.-i. Kamei, Y.-C. 
Chen, M. Ohashi, M. Wang, M. A. Garcia, X.-Z. Zhao, C. K. F. Shen, H.-R. Tseng, ACS nano 
2010, 4, 6235. 
[111] a) S. Ding, N. Anton, T. F. Vandamme, C. A. Serra, Expert Opinion on Drug Delivery 
2016, 13, 1447; b) Y. Kim, B. Lee Chung, M. Ma, W. J. M. Mulder, Z. A. Fayad, O. C. 
Farokhzad, R. Langer, Nano Letters 2012, 12, 3587. 





































































[113] L. Zhang, W. Wang, X.-J. Ju, R. Xie, Z. Liu, L.-Y. Chu, RSC Advances 2015, 5, 5638. 























































































((For Essays, Feature Articles, Progress Reports, and Reviews, please insert up to three 
author biographies and photographs here, max. 100 words each)) 
 




Flavia Fontana (MSc. Pharm.) is a graduate student in Associate Professor Santos' lab, at the 
Faculty of Pharmacy, University of Helsinki (Finland). She obtained her Master's Degree in 
Medicinal Chemistry and Pharmaceutical Technology at the University of Pavia (Italy). Her 
main research interests are the development of innovative biohybrid nanovaccines, 





João P. Martins (MSc.) graduated in Biomedical Engineering from the Faculty of Engineering 
of University of Porto (FEUP), Portugal. Currently, as a PhD student in Professor Hélder A. 
Santos’ lab at the University of Helsinki, he has been developing his research activity towards 
the development of microfluidic-based drug delivery systems to help making oral delivery of 








































































Prof. Hélder A. Santos obtained his Doctor of Science in Technology (Chem. Eng.) in 2007 
from the Helsinki University of Technology, Finland. Currently, he is also the Head of the 
Division of Pharmaceutical Chemistry and Technology, the Head of the Preclinical Drug 
Formulation and Analysis Group, and the Head of the Nanomedicines and Biomedical 
Engineering Group, all at the Faculty of Pharmacy, University of Helsinki, Finland. Prof. 
Santos is also a HiLIFE Fellow (2017-2020), University of Helsinki. His scientific expertise 
lies in the development of nanoparticles/nanomedicines for biomedical and healthcare 
applications, particularly porous silicon nanomaterials for simultaneous controlled drug 





































































Microfluidics displays multiple applications in the treatment of complex diseases. The 
nuts and bolts to engineer a platform for the production of drug delivery system are analyzed. 
Moreover, the application of microfluidics platforms as sensor and for the production of 
nanotherapeutics in cancer, immunotherapy, diabetes and other diseases are reviewed. Finally, 
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